Evidence map›Paper›PMID 34518155›Full record

ArticleBMJ open diabetes research & care2021

Plasma N-glycome shows continuous deterioration as the diagnosis of insulin resistance approaches.

Ana Cvetko, Massimo Mangino, Marko Tijardović, Domagoj Kifer, Mario Falchi, Toma Keser, Markus Perola, Tim D Spector, Gordan Lauc, Cristina Menni and 1 more

Open access · goldAbstract read
In one paragraph

Article in BMJ open diabetes research & care, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 34 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. TheBiomolecules · 2023
    Article
  12. Article
  13. Article
  14. High-Throughput Glycomic Methods.Chemical reviews · 2022
    Review
  15. Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 4 countries.

Ana Cvetko *University of Zagreb Faculty of Pharmacy and Biochemistry, Zagreb, Croatia.ORCID 0000-0002-7134-2484
Massimo Mangino *Department of Twin Research and Genetic Epidemiology, King's College London, London, UK.
Marko TijardovićUniversity of Zagreb Faculty of Pharmacy and Biochemistry, Zagreb, Croatia.
Domagoj KiferUniversity of Zagreb Faculty of Pharmacy and Biochemistry, Zagreb, Croatia.
Mario FalchiDepartment of Twin Research and Genetic Epidemiology, King's College London, London, UK.
Toma KeserUniversity of Zagreb Faculty of Pharmacy and Biochemistry, Zagreb, Croatia.
Markus PerolaNational Institute for Health and Welfare, Helsinki, Finland.
Tim D SpectorDepartment of Twin Research and Genetic Epidemiology, King's College London, London, UK.
Gordan LaucUniversity of Zagreb Faculty of Pharmacy and Biochemistry, Zagreb, Croatia.
Cristina Menni *Department of Twin Research and Genetic Epidemiology, King's College London, London, UK.
Olga Gornik *University of Zagreb Faculty of Pharmacy and Biochemistry, Zagreb, Croatia ogornik@pharma.unizg.hr.
University of Zagreb · HRKing's College London · GBFinnish Institute for Health and Welfare · FI

Funding

Wellcome Trust
6 · The paper itself

Abstract

introductionPrediction of type 2 diabetes mellitus (T2DM) and its preceding factors, such as insulin resistance (IR), is of great importance as it may allow delay or prevention of onset of the disease. Plasma protein N-glycome has emerged as a promising predictive biomarker. In a prospective longitudinal study, we included patients with a first diagnosis of impaired glucose metabolism (IR or T2DM) to investigate the N-glycosylation's predictive value years before diabetes development. RESEARCH DESIGN AND

methodsPlasma protein N-glycome was profiled by hydrophilic interaction ultra-performance liquid chromatography in 534 TwinsUK participants free from disease at baseline. This included 89 participants with incident diagnosis of IR or T2DM during the follow-up period (7.14±3.04 years) whose last sample prior to diagnosis was compared using general linear regression with 445 age-matched unrelated controls. Findings were replicated in an independent cohort. Changes in N-glycome have also been presented in connection with time to diagnosis.

resultsEight groups of plasma N-glycans were different between incident IR or T2DM cases and controls (p<0.05) after adjusting for multiple testing using Benjamini-Hochberg correction. These differences were noticeable up to 10 years prior to diagnosis and are changing continuously as becoming more expressed toward the diagnosis. The prediction model was built using significant glycan traits, displaying a discriminative performance with an area under the receiver operating characteristic curve of 0.77.

conclusionsIn addition to previous studies, we showed the diagnostic potential of plasma N-glycome in the prediction of both IR and T2DM development years before the clinical manifestation and indicated the continuous deterioration of N-glycome toward the diagnosis.

Indexed as

Diabetes Mellitus, Type 2Insulin ResistanceCohort StudiesHumansLongitudinal StudiesProspective Studiesdiabetes mellitusglycosylationinsulin resistancepreventive medicinetype 2

Identifiers

PMID34518155
PMCPMC8438737
OpenAlexW3198927554

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.